{
  "id": "ni-rads-pet-ct-9bdcab",
  "title": "NI-RADS PET/CT",
  "source": "ni-rads-pet-ct.html",
  "blocks": [
    {
      "type": "heading",
      "level": 2,
      "text": "Essentials"
    },
    {
      "type": "paragraph",
      "text": "Source: NI-RADSTM PET/CT Management Table (Revised January 2021)."
    },
    {
      "type": "list",
      "items": [
        "Designed for post-treatment head & neck cancer surveillance after definitive/curative therapy (not during treatment).",
        "If primary is unknown, use P-unknown primary; if primary cannot be assessed (dental artifact, motion, outside FOV), use P-x.",
        "Discordance rule applies only if original tumor was FDG-avid.",
        "Residual nodal tissue = node abnormal pre-treatment; hypo-enhancement/irregular borders without FDG often treatment response.",
        "New or enlarging node (not present pre-treatment) with irregular borders or necrosis is definitively abnormal."
      ]
    },
    {
      "type": "heading",
      "level": 2,
      "text": "NI-RADS PET/CT Categories"
    },
    {
      "type": "paragraph",
      "text": "Primary site and neck categories with imaging findings and management."
    },
    {
      "type": "paragraph",
      "text": "*Focal mucosal abnormalities on initial post-treatment PET/CECT often treatment-related -> usually 2a and direct inspection. Later mass-like/nodular mucosal abnormality may warrant 3. **PET/CECT discordance rule only if original tumor FDG-avid. ***Definitive abnormal morphology = new necrosis or gross ENE with invasion of adjacent structures."
    },
    {
      "type": "heading",
      "level": 2,
      "text": "Quick Notes"
    },
    {
      "type": "list",
      "items": [
        "Residual nodal tissue may remain hypoenhancing/irregular post-treatment; if no FDG uptake, likely response.",
        "New/enlarging node during surveillance with irregular borders/necrosis is definitively abnormal.",
        "Use 2b or neck 2 for deep ill-defined soft tissue with only mild/moderate FDG or discordant PET/CECT.",
        "High suspicion (3): discrete mass or intense FDG at primary; new/enlarging nodes with abnormal morphology or intense FDG."
      ]
    },
    {
      "type": "heading",
      "level": 2,
      "text": "Footnotes & Clarifications"
    },
    {
      "type": "list",
      "items": [
        "Focal mucosal abnormalities on initial post-treatment PET/CECT are often treatment-related -> usually assign 2a with direct inspection. Later mass-like/nodular mucosal changes may warrant 3.",
        "PET/CECT discordance rule applies only if the original tumor was FDG-avid.",
        "Definitive abnormal morphology in nodes = new necrosis or gross extranodal extension (ENE) invading adjacent structures.",
        "Residual nodal tissue: abnormal pre-treatment node; hypoenhancement/irregular borders without FDG uptake often indicate response.",
        "New or enlarging node: develops during surveillance (not present pre-treatment); irregular borders or necrosis are definitively abnormal.",
        "Primary unknown: designate P-unknown primary; if primary cannot be assessed (dental artifact, motion, outside FOV), use P-x.",
        "NI-RADS categories are intended for use after definitive/curative treatment; not designed for use during treatment."
      ]
    },
    {
      "type": "heading",
      "level": 2,
      "text": "Inline Workflow"
    },
    {
      "type": "paragraph",
      "text": "Evaluate PET/CT findings -> assign NI-RADS 0-4 -> apply management; note special cases and timing."
    },
    {
      "type": "heading",
      "level": 2,
      "text": "Source"
    },
    {
      "type": "paragraph",
      "text": "NI-RADSTM PET/CT Management Table (Revised January 2021). PDF: link."
    }
  ]
}
